Galenicum

Established in 2003 in Barcelona, Galenicum has grown from a small entrepreneurial project into a global specialty pharmaceutical group with a presence in more than fifty countries. The company’s purpose has remained consistent from the start: to make medicines more accessible while maintaining high quality across development, manufacturing, and distribution. Over the years, Galenicum has built a diversified business ecosystem that includes API trading, R&D for finished dosage forms, regulatory affairs, manufacturing, supply, and commercialisation.

A key asset in this growth is the company’s manufacturing site in San Agustín del Guadalix, Madrid, operated by GalenicumSAG. This plant is designed for multiple pharmaceutical formats and has a production capacity exceeding 50 million packs annually. Its portfolio of certifications includes GMP for Europe, ANVISA for Brazil, and GILS for Russia, underlining its readiness for regulated international markets. The company’s workforce was estimated at 687 employees as of December 2025, which provides a solid benchmark for 2026 planning and market presentation